DEVELOPING News: Acceleron negotiating $11B buyout; 11 promising biotech startups; Changes galore at Novartis; #ESMO21 highlights; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
This week I’ve been detached from daily news writing to focus on an upcoming special report on China (and taking some time to celebrate the Mid-Autumn Festival here in Hong Kong), but as you can see below, the rest of the team had lots of news and specials for you. If you haven’t, be sure to watch our online events for #ESMO21 and Endpoints 11, both available on demand. You can find the ESMO panel moderated by managing editor Kyle Blankenship here and the fireside chat hosted by founder John Carroll here, featuring a slate of guests with plenty of wisdom to impart.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.